Spotlight on Oncology

Credits: 1.00 CME / CNE
The Increasing Role of Biosimilars in Oncology
Sanjiv Agarwala, MD
AcademicCME

The Increasing Role of Biosimilars in Oncology

Start

Activity Details

Free CME/CNE
1.0 AMA PRA Category 1 Credit
1.0 Contact Hour
Released: June 15, 2018
Expires: September 17, 2019
1 hour to complete

Accredited By

Target Audience

Oncologists, primary care physicians, internists and advanced practice providers, including NPs and PAs, responsible for the diagnosis, treatment or management of patients with various cancers

Learning Objectives

  • Understand the fundamentals of biosimilars in oncology, including bioequivalence, totality of evidence, and interchangeability.
  • Evaluate the current clinical trial data of biosimilars for the treatment of various oncologic therapeutic areas.
  • Utilize the health care team and shared decision making to achieve improved outcomes in patients with various cancers.

Activity Description

This continuing education activity will focus on recent clinical trial data as well as therapeutic advances in the increasing role of biosimilars in oncology. The three expert faculty will review the fundamentals of biosimilars in oncology, including bioequivalence, totality of evidence, and interchangeability. A review of current clinical trial data of biosimilars for the treatment of various oncologic therapeutic areas will be presented. The faculty will discuss how to utilize the health care team and shared decision making to achieve improved outcomes in patients with various cancers. Upon completion of this activity, learners will gain knowledge on how to implement biosimilars in their treatment strategies for oncology patients.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding use of biosimilars and their role in modern day medicine.

Agenda

  1. A Scientific Overview of Biosimilars in Oncology
  2. A Clinical Analysis of Emerging Biosimilars in Oncology
  3. The Importance of Utilizing the Health Care Team and Shared Decision Making to Achieve Improved Outcomes

Faculty

Sanjiv S. Agarwala, MD
Chief of Medical Oncology and Hematology
St Luke's University Hospital and Health Network
Professor of Medicine
Temple University School of Medicine
Philadelphia, Pennsylvania


Amy Goodrich, RN, BSN, MSN, CRNP-AC
Research Associate
The Johns Hopkins School of Medicine
Nurse Practitioner
The Sidney Kimmel Cancer Center at Johns Hopkins
Baltimore, Maryland


Wasif M. Saif, MD, MBBS
Professor of Medicine
Director, GI Oncology Program
Program Leader, Experimental Therapeutics
Tufts Medical Center
Boston, Massachusetts


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:

Sanjiv S. Agarwala, MD
Nothing to disclose.

Amy Goodrich, RN, BSN, MSN, CRNP-AC
Consultant/Advisor: Gilead
Speaker's Bureau: Gilead

Wasif M. Saif, MD, MBBS
Grant/Research Support: TAIHO ONCOLOGY, INC.
Speaker's Bureau: TAIHO ONCOLOGY, INC.

Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Emma Boring; Chelsey Benedek; and Kim Cheramie, MSN, RN-BC, hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AcademicCME designates this enduring material for a maximum of 1.0 CNE contact hour.

Method of Participation

In order to claim credit, participants must complete the following:

  • Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  • Complete the Pre-Activity Questions.
  • Read or Review the activity content.
  • Complete the Post-Activity Test Questions and Evaluation.
  • Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
  • All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.

Statement of Commercial Support

This activity has been supported by educational grants from Amgen Inc. and Boehringer Ingelheim.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME, Amgen Inc. and Boehringer Ingelheim do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CNE inquiries or special needs, please contact admin@academiccme.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Oncology Presentations

0.50 CME
University of Nebraska Medical Center
Podium to Practice: Updates from Chicago Regarding Recent Advances in CAR T-cell Therapy for the Treatment of Hematologic Malignancies

Podium to Practice: Updates from Chicago Regarding Recent Advances in CAR T-cell Therapy for the Treatment of Hematologic Malignancies

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit
Released: July 17, 2019
Expires: July 17, 2020
30 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Provider

This activity is jointly provided by the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who are interested in the use of CAR T-cell therapy for the treatment of patients with hematologic malignancies.

Learning Objectives

After completing this activity, participants should be better able to:

  • Review clinical trial data of current and emerging CAR T-cell therapies that are being investigated in patients with hematologic malignancies, including lymphoma, leukemia, and multiple myeloma
  • Discuss the potential for using CAR T-cell-based therapies in patients with other malignancies
  • Discuss common adverse events that are associated with CAR T-cell therapy, and develop strategies to mitigate such adverse events

Activity Description

Podium to Practice is a discussion among two renowned experts actively engaged in clinical trials and the management of patients with CAR T cells. This exchange features expert summary and interpretation of data presented during the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, and provides guidance on the optimal use of CAR T cells for patients with hematologic malignancies.

Statement of Educational Need

CAR T cells have emerged as a highly effective therapy in patients with hematologic malignancies and show promise in patients with solid tumors. However, multiple CAR T technologies are under investigation, all with various doses, lymphodepleting chemotherapy, disease subtypes under exploration, and adverse event profiles. Thus, clinicians treating patients with these agents need expert guidance to evaluate clinical data of CAR T therapy and plan strategies to appropriately integrate these approaches into practice now and as they become available.

Faculty

Matthew Lunning, DO - Moderator
Associate Professor
Internal Medicine
Division of Oncology & Hematology
University of Nebraska Medical Center
Omaha, Nebraska

Consulting Fees: AbbVie, Inc., Bayer, Celgene Corporation, DAVA, Gilead Sciences, Inc., Janssen, Juno Therapeutics, Kite Pharma, Novartis, OncLive, Portola, Seattle Genetics, Spectrum Pharmaceuticals, TG Therapeutics, Vaniam Group, Verastem
Grants/Research Support: Celgene Corporation, Curis, Janssen Scientific Affairs, LLC, Juno Therapeutics, MiRagen, TG Therapeutics


Reem Karmali, MD, MS
Assistant Professor
Northwestern University Feinberg School of Medicine
Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois

Advisory Board: Celgene Corporation, Gilead Sciences, Inc., Juno Therapeutics, Kite Pharma
Grants/Research Support: Bristol-Myers Squibb Company, Celgene Corporation, Gilead Sciences, Inc., Juno Therapeutics, Kite Pharma, Takeda Pharmaceutical Company Ltd
Speakers Bureau: Celgene Corporation, Gilead Sciences, Inc., Juno Therapeutics, Kite Pharma


Conflict of Interest Policy/Disclosure Statement

As a provider accredited by ACCME, the University of Nebraska Medical Center (UNMC), Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC, Center for Continuing Education.

The following indicates the disclosure declaration information and the nature of those commercial relationships.

All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by educational grants from Celgene Corporation and Gilead Sciences, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

This program may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

Contact Information for Questions About the Activity

University of Nebraska Medical Center, Center for Continuing Education
Brenda Ram, CMP, CHCP
bram@unmc.edu
402-559-9250

Bio Ascend
cme@bioascend.com

1.00 CME / CNE / CPE
Rush University Medical Center
Expert Perspectives in the Management of Chronic Lymphocytic Leukemia: Integrating Current and Emerging Agents/Regimens to Develop Evidence Based Clinical Management Strategies

Expert Perspectives in the Management of Chronic Lymphocytic Leukemia: Integrating Current and Emerging Agents/Regimens to Develop Evidence Based Clinical Management Strategies

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: July 2, 2019
Expires: July 1, 2020
1 hour to complete

Accredited by

Rush University Medical Center

Co-provided by

Target Audience

This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with Chronic Lymphocytic Leukemia.

Learning Objectives

After completing this program, participants should be able to:

1: Apply the latest data to risk stratify and optimize treatment plans for patients with CLL based on prognostic and predictive markers

2: Differentiate between first-line and relapsed/refractory treatment approaches for the treatment of CLL using the latest evidence-based guidelines

3: Explain the emerging clinical data and ongoing trials on novel agents and therapeutic strategies that have the potential to improve patient outcomes for patients with CLL

4: Summarize evidence-based management strategies that can be used to identify and treat acute and long-term complications associated with CLL treatment including: barriers to treatment, adherence, comorbidities, advanced age, etc.

Activity Description

This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of CLL. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.

Statement of Educational Need

Taking into consideration the continued evolution of therapeutic modalities and management strategies for CLL along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with CLL, allowing for ease of assessment and incorporation into clinical practice.

Faculty

Jonathon B. Cohen, MD, MS (Course Director)
Department of Hematology and Medical Oncology
Emory University
Winship Cancer Institute
Atlanta, GA


Conflict of Interest Policy/Disclosure Statement

Jonathon B. Cohen, MD, MS, has disclosed having financial arrangements or affiliations with the following commercial interest(s) whose products or services may be mentioned in this activity.

Advisor: Janssen, Genentech
Research Funding: Genentech

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by educational grants from AbbVie, Inc, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and TG Therapeutics.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions about the Activity

info@plexuscomm.com

0.25 CME
AXIS
Expert Answers to Common Questions for Optimizing the Use of CDK4 and CDK6 Inhibitors for Metastatic Breast Cancer

Expert Answers to Common Questions for Optimizing the Use of CDK4 and CDK6 Inhibitors for Metastatic Breast Cancer

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit
Released: March 26, 2019
Expires: March 25, 2020
15 minutes to complete

Provided by

This educational activity is provided by

Target Audience

This activity is intended for medical oncologists and other healthcare professionals who treat or manage advanced or metastatic breast cancer.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Describe the mechanism of action of cyclin-dependent kinase 4/6 inhibitors, including differences among available and emerging agents
  • Compare and contrast the dosing and efficacy of cyclin-dependent kinase 4/6 inhibitors for the treatment of hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced or metastatic breast cancer
  • Select the appropriate cyclin-dependent kinase 4/6 inhibitor for patients according to their efficacy, safety, and patient characteristics
  • Identify common toxicities of cyclin-dependent kinase 4/6 inhibitors for the treatment of hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer, including gastrointestinal toxicity and neutropenia

Activity Description

Recently, there have been significant advances in the development of agents that target critical pathways involved in resistance to endocrine therapy in HR-positive/HER2-negative breast cancer, such as cyclin-dependent kinase (CDK) 4/6 inhibitors,  palbociclib, abemaciclib, and ribociclib.

AXIS routinely collects and analyzes data gathered from participants in our live grand rounds programs. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment planning to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent grand rounds series on CDK4/6 inhibitors for the treatment of advanced HR-positive/HER2-negative breast cancer.

Statement of Educational Need

The goal of this activity is to provide expert perspective on frequently asked questions pertaining to the use of CDK4 and CDK6 inhibitors for the treatment of HR-positive/HER2-negative advanced or metastatic breast cancer so clinicians gain an enhanced understanding of this disease to make the best possible treatment choices with their patients.

Faculty

Adam M. Brufsky, MD, PhD, FACP
Professor of Medicine / Associate Chief, Hematology-Oncology / Associate Director, Translational Research
University of Pittsburgh School of Medicine
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania

Disclosure of Conflicts of Interest

AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Adam M. Brufsky, MD, PhD, FACP
  • Adam M. Brufsky, MD, PhD, FACP, reported a financial interest/relationship or affiliation in the form of: Received consulting fees from Lilly USA; Novartis Pharmaceuticals Corp; Pfizer, Inc; Amgen, Inc; and AstraZeneca Pharmaceuticals LP.

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; Stephanie Sutphin, PharmD, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation for Physicians

AXIS Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

AXIS Contact Information

For information about the certification of this activity, please contact AXIS at info@axismeded.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME / CNE
AXIS
Using “Rapid Progression” and Response Levels as Prognostic Markers in Selecting Optimal Second-Line Therapy for NSCLC

Using “Rapid Progression” and Response Levels as Prognostic Markers in Selecting Optimal Second-Line Therapy for NSCLC

Start

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credits
0.5 Contact Hour(s)
Released: August 8, 2018
Expires: August 7, 2019
30 minutes to complete

Provided by

This educational activity is provided by

Target Audience

This activity is intended for medical oncologists, thoracic oncologists, pulmonologists, pathologists, oncology nurses, and other healthcare professionals involved in the treatment of NSCLC.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Analyze treatment options for patients with advanced NSCLC that does not have an actionable mutation target and has progressed on or after prior platinum-based therapy
  • Develop treatment plans for patients with advanced NSCLC without targetable activating mutations that has progressed on or after prior platinum-based therapy according to clinical practice guidelines
  • Select appropriate treatment for NSCLC without targetable activating mutations that has progressed rapidly on initial platinum-based therapy

Activity Description

Lung cancer continues to be the leading cause of cancer death in the United States, accounting for 27% of all cancer deaths in males and 25% in females. Non–small cell lung cancer (NSCLC) accounts for approximately 80% of lung cancer cases. The prognosis of patients with NSCLC is poor; the 5-year overall survival (OS) rate is 5% for those with metastatic disease and 18% across all stages. Approximately 70% of patients with lung cancer have advanced or metastatic disease at initial diagnosis.

The discovery of predictive biomarkers, such as sensitizing epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, ROS1 rearrangements, and BRAF mutations has led to an improvement in OS and progression-free survival by identifying subgroups of patients who benefit from targeted treatment. “Although recent advances have improved clinical outcomes for patients with tumors harboring targetable driver mutations, most NSCLC tumors lack these mutations, highlighting the need for novel therapeutic interventions… Patients with advanced NSCLC that is aggressive and rapidly progresses after first-line treatment have a poor prognosis and have been studied in several trials” (Reck et al, 2017).

This activity will review available treatment options, current guideline recommendations, and recent data about disease that has progressed rapidly on initial therapy to inform appropriate treatment selection.

Statement of Educational Need

The goal of this activity is to provide clinicians with the latest advances in the treatment of patients with advanced NSCLC without targetable activating mutations that has progressed on prior platinum-based therapy, including patients with disease that has progressed rapidly on initial therapy.

Faculty

Stephen V. Liu, MD
Associate Professor of Medicine
Lombardi Comprehensive Cancer Center
Georgetown University School of Medicine
Washington, DC


Disclosure of Conflicts of Interest

AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Stephen V. Liu, MD, reported a financial interest/relationship or affiliation in the form of Advisor/Consultant, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Co, Celgene Corp, Genentech/Roche, Ignyta, Lilly USA, Pfizer, Inc, Taiho Pharmaceutical Co, Ltd, Takeda Oncology; Contracted research, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Corvus Pharmaceuticals, Esanex Inc, Genentech, Inc, Ignyta, Lycera, MedImmune, Merck & Co, Inc, OncoMed Pharmaceuticals, Pfizer, Inc, Threshold Pharmaceuticals.

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn Haas, PhD, RN, CNS, ANP-BC; and Stephanie Sutphin, PharmD,hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Designation of Credit

Credit Designation for Physicians
AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 100% and the post-activity evaluation, your certificate will be made available immediately.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

AXIS Contact Information

For information about the certification of this activity, please contact AXIS at info@axismeded.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.25 CME / MOC / CNE
The France Foundation
PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Understanding and Applying PARP Inhibitor Data to Selection and Monitoring

PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Understanding and Applying PARP Inhibitor Data to Selection and Monitoring

Start

Activity Details

Free CME/MOC/CNE
0.25 AMA PRA Category 1 Credits™/
MOC Points
0.25 Contact Hour(s)
Released: December 20, 2018
Expires: December 19, 2019
15 minutes to complete

Jointly Provided by

Target Audience

This educational initiative is intended for oncologists, nurse practitioners, and nurses who manage patients with metastatic breast cancer (MBC).

Learning Objectives

  • Use BRCA and other key genomic tests in an appropriate and timely manner for patients with MBC
  • Interpret the results of genomic testing accurately, including working effectively with genetic counselors
  • Recommend PARP inhibitor use appropriately on the basis of key data/characteristics and recommendations in advanced breast cancer (BC)
  • Discuss results of genetic testing and implications of PARP inhibitor therapy with patients and families

Activity Description

This case-based webinar includes implications of genetic testing for treatment decisions, and reviews the safety and efficacy of FDA-approved PARP inhibitors for patients with metastatic or advanced breast cancer with germline BRCA mutations.

Statement of Educational Need

MBC has a five-year survival rate of only 26%, and stands in stark contrast to localized and regionally advanced diseases. Those have a five-year survival rate of 99% and 85%, respectively, thanks to therapy improvements over several decades. Oncology clinicians continue to face several challenges in optimizing personalized, targeted treatment for MBC in a climate where data on biomarkers and evolving treatment strategies continue to emerge at a rapid pace.

Faculty

Joy Larsen Haidle, MS, CGC
Ruth M. O’Regan, MD
Associate Director, Clinical Research
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

The following faculty report that they have relevant financial relationships to disclose:
  • Ruth O’Regan, MD, has done contract research for Eisai, Novartis and Pfizer, Inc. Dr. O’Regan has served as an advisor for Genentech, Immunogenics, Lilly, MacroGenics, Novartis, Pfizer, Inc. and Puma.


Jennie Petruney, ANP
Nurse Practitioner
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina

The following faculty report that they have no relevant financial relationships to disclose:
  • Jennie Petruney, ANP

MOC Reviewers

Theodore Bruno, MD
Chief Medical Officer
The France Foundation
Old Lyme, Connecticut

The following faculty report that they have relevant financial relationships to disclose:
  • Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.


Patrick Thomas Grogan, MD, PhD
Hematology/Oncology Fellow
University of Wisconsin Hospital and Clinics
Department of Medicine
Division of Hematology/Oncology
Madison, Wisconsin

The following faculty report that they have no relevant financial relationships to disclose:
  • Patrick Thomas Grogan, MD, PhD

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF), the Association of Community Cancer Centers (ACCC) and the Oncology Nursing Society (ONS) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF, ACCC and ONS resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF, ACCC and ONS seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF, ACCC and ONS are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of TFF, ACCC and ONS. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

The Oncology Nursing Society is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's (ANCC) Commission on Accreditation.

ONS is approved as a provider of continuing education by the California Board of Registered Nursing, Provider #2850.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification
ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Participants in PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Understanding and Applying PARP Inhibitor Data to Selection and Monitoring can earn a maximum of 0.25 contact hours of CNE upon the successful completion of this continuing education activity. No partial credit will be given. Participants must view sessions in their entirety and submit a completed evaluation within the specified time frame to receive CNE credit. NOTE: It is not required to complete all three parts of the series to claim your CNE certificate for one of the parts.

ANCC

ILNA Information 
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. CNE sessions have been classified into the following ILNA categories for all certification renewals (OCN, BMTCN, AOCNP, AOCNS, CBCN, CPHON)  

  • Coordination of Care – 0.25 points
  • Diagnosis and Staging – 0.25 points
  • Treatment – 0.25 points

Method of Participation / How to Receive Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of at least 50% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.

Statement of Commercial Support

This activity is supported by an educational grant from Pfizer, Inc.

Disclaimer Statement/ Disclosure of Unlabeled Use

TFF, ACCC and ONS require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF, ACCC and ONS do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME / MOC / CNE
The France Foundation
PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Future Vision

PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Future Vision

Start

Activity Details

Free CME/MOC/CNE
0.50 AMA PRA Category 1 Credits™/
MOC Points
0.50 Contact Hour(s)
Released: December 20, 2018
Expires: December 19, 2019
30 minutes to complete

Jointly Provided by

Target Audience

This educational initiative is intended for oncologists, nurse practitioners, and nurses who manage patients with metastatic breast cancer (MBC).

Learning Objectives

  • Use BRCA and other key genomic tests in an appropriate and timely manner for patients with MBC
  • Interpret the results of genomic testing accurately, including working effectively with genetic counselors
  • Recommend PARP inhibitor use appropriately on the basis of key data/characteristics and recommendations in advanced breast cancer (BC)
  • Discuss results of genetic testing and implications of PARP inhibitor therapy with patients and families

Activity Description

This webinar provides an overview of PARP inhibitor therapy for patients with breast cancer, including use as single-agent therapy, and ongoing studies evaluating PARP inhibitors in combination with chemotherapy and immunotherapy for this patient population.

Statement of Educational Need

MBC has a five-year survival rate of only 26%, and stands in stark contrast to localized and regionally advanced diseases. Those have a five-year survival rate of 99% and 85%, respectively, thanks to therapy improvements over several decades. Oncology clinicians continue to face several challenges in optimizing personalized, targeted treatment for MBC in a climate where data on biomarkers and evolving treatment strategies continue to emerge at a rapid pace.

Faculty

Joy Larsen Haidle, MS, CGC
Ruth M. O’Regan, MD
Associate Director, Clinical Research
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

The following faculty report that they have relevant financial relationships to disclose:
  • Ruth O’Regan, MD, has done contract research for Eisai, Novartis and Pfizer, Inc. Dr. O’Regan has served as an advisor for Genentech, Immunogenics, Lilly, MacroGenics, Novartis, Pfizer, Inc. and Puma.


Carol K. Tweed, MD
Medical Oncologist
Anne Arundel Medical Center
Annapolis, Maryland

The following faculty report that they have relevant financial relationships to disclose:
  • Carol K. Tweed, MD, has served on an advisory board for AstraZeneca. She has served on a Non-CE speakers bureau for Genomic Health.

MOC Reviewers

Theodore Bruno, MD
Chief Medical Officer
The France Foundation
Old Lyme, Connecticut

The following faculty report that they have relevant financial relationships to disclose:
  • Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.


Patrick Thomas Grogan, MD, PhD
Hematology/Oncology Fellow
University of Wisconsin Hospital and Clinics
Department of Medicine
Division of Hematology/Oncology
Madison, Wisconsin

The following faculty report that they have no relevant financial relationships to disclose:
  • Patrick Thomas Grogan, MD, PhD

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF), the Association of Community Cancer Centers (ACCC) and the Oncology Nursing Society (ONS) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF, ACCC and ONS resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF, ACCC and ONS seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF, ACCC and ONS are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of TFF, ACCC and ONS. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

The Oncology Nursing Society is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's (ANCC) Commission on Accreditation.

ONS is approved as a provider of continuing education by the California Board of Registered Nursing, Provider #2850.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification
ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 Medical Knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Participants in PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Future Vision can earn a maximum of 0.50 contact hours of CNE upon the successful completion of this continuing education activity. No partial credit will be given. Participants must view sessions in their entirety and submit a completed evaluation within the specified time frame to receive CNE credit. NOTE: It is not required to complete all three parts of the series to claim your CNE certificate for one of the parts.

ANCC

ILNA Information 
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. CNE sessions have been classified into the following ILNA categories for all certification renewals (OCN, BMTCN, AOCNP, AOCNS, CBCN, CPHON)  

  • Diagnosis and Staging – 0.50 points
  • Treatment – 0.50 points

Method of Participation / How to Receive Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of at least 50% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.

Statement of Commercial Support

This activity is supported by an educational grant from Pfizer, Inc.

Disclaimer Statement/ Disclosure of Unlabeled Use

TFF, ACCC and ONS require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF, ACCC and ONS do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.75 CME / MOC / CNE
The France Foundation
PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Appropriate Genetic Testing and Implications for Targeted Therapy Use

PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Appropriate Genetic Testing and Implications for Targeted Therapy Use

Start

Activity Details

Free CME/MOC/CNE
0.75 AMA PRA Category 1 Credits™/
MOC Points
0.75 Contact Hour(s)
Released: December 20, 2018
Expires: December 19, 2019
45 minutes to complete

Jointly Provided by

Target Audience

This educational initiative is intended for oncologists, nurse practitioners, and nurses who manage patients with metastatic breast cancer (MBC).

Learning Objectives

  • Use BRCA and other key genomic tests in an appropriate and timely manner for patients with MBC
  • Interpret the results of genomic testing accurately, including working effectively with genetic counselors
  • Recommend PARP inhibitor use appropriately on the basis of key data/characteristics and recommendations in advanced breast cancer (BC)
  • Discuss results of genetic testing and implications of PARP inhibitor therapy with patients and families

Activity Description

This case-based webinar reviews criteria for BRCA1/2 testing, the importance of obtaining family history for patients with cancer, interpretation of genetic testing results for patients with metastatic breast cancer and their families, and ways to access genetic services.

Statement of Educational Need

MBC has a five-year survival rate of only 26%, and stands in stark contrast to localized and regionally advanced diseases. Those have a five-year survival rate of 99% and 85%, respectively, thanks to therapy improvements over several decades. Oncology clinicians continue to face several challenges in optimizing personalized, targeted treatment for MBC in a climate where data on biomarkers and evolving treatment strategies continue to emerge at a rapid pace.

Faculty

Joy Larsen Haidle, MS, CGC
Joy Larsen Haidle, MS, CGC
Genetic Counselor
North Memorial Health Cancer Center
Robbinsdale, Minnesota

The following faculty report that they have no relevant financial relationships to disclose:
  • Joy Larsen Haidle, MS, CGC


Carol K. Tweed, MD
Medical Oncologist
Anne Arundel Medical Center
Annapolis, Maryland

The following faculty report that they have relevant financial relationships to disclose:
  • Carol K. Tweed, MD, has served on an advisory board for AstraZeneca. She has served on a Non-CE speakers bureau for Genomic Health.

MOC Reviewers

Theodore Bruno, MD
Chief Medical Officer
The France Foundation
Old Lyme, Connecticut

The following faculty report that they have relevant financial relationships to disclose:
  • Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.


Patrick Thomas Grogan, MD, PhD
Hematology/Oncology Fellow
University of Wisconsin Hospital and Clinics
Department of Medicine
Division of Hematology/Oncology
Madison, Wisconsin

The following faculty report that they have no relevant financial relationships to disclose:
  • Patrick Thomas Grogan, MD, PhD

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF), the Association of Community Cancer Centers (ACCC) and the Oncology Nursing Society (ONS) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF, ACCC and ONS resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF, ACCC and ONS seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF, ACCC and ONS are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of TFF, ACCC and ONS. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

The Oncology Nursing Society is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's (ANCC) Commission on Accreditation.

ONS is approved as a provider of continuing education by the California Board of Registered Nursing, Provider #2850.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification
ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Participants in PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Appropriate Genetic Testing and Implications for Targeted Therapy Use can earn a maximum of 0.75 contact hours of CNE upon the successful completion of this continuing education activity. No partial credit will be given. Participants must view sessions in their entirety and submit a completed evaluation within the specified time frame to receive CNE credit. NOTE: It is not required to complete all three parts of the series to claim your CNE certificate for one of the parts.

ANCC

ILNA Information 
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. CNE sessions have been classified into the following ILNA categories for all certification renewals (OCN, BMTCN, AOCNP, AOCNS, CBCN, CPHON).

  • Diagnosis and Staging – 0.75 points 
  • Treatment – 0.75 points

Method of Participation / How to Receive Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of at least 50% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.

Statement of Commercial Support

This activity is supported by an educational grant from Pfizer, Inc.

Disclaimer Statement/ Disclosure of Unlabeled Use

TFF, ACCC and ONS require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF, ACCC and ONS do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

1.00 CME / CNE / CPE
Rush University Medical Center
Expert Perspectives on Improving Treatment of Patients with B-cell Non Hodgkin Lymphomas

Expert Perspectives on Improving Treatment of Patients with B-cell Non Hodgkin Lymphomas

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: November 9, 2018
Expires: November 8, 2019
60 minutes to complete

Accredited By

Rush University Medical Center

Co-provided By

Target Audience

Healthcare providers who are involved with the treatment of patients with B-cell lymphomas

Learning Objectives

After completing this program, participants should be able to:

  • Summarize current best-practice approaches for treatment of patients with different subtypes of indolent and aggressive B-cell non-Hodgkin lymphomas (NHLs)
  • Asses recent clinical advances and emerging treatment options for the management of B-cell NHLs, including next generation mAbs, BTK inhibitors, PI3K inhibitors, IMiDs, Bcl-2 inhibitors, and ongoing clinical trials
  • Evaluate patient, disease, and treatment-related considerations to optimize patient outcomes while providing the best standard of care for patients with B-cell NHLs

Activity Description

This activity provides healthcare providers with much needed professional education on treatment algorithms; recent clinical advances, emerging treatments, and clinical trials; as well as considerations to optimize patient outcomes while providing the best standard of care for patients with B-cell NHLs.

Faculty

Thomas E. Witzig, MD
Professor of Medicine Mayo Clinic College of Medicine
Co-PI, University of Iowa/Mayo Clinic Lymphoma SPORE
Deputy Director of Clinical Research, Mayo Clinic Cancer Center
Rochester, MN


Conflict of Interest Policy/Disclosure Statement

Unapproved Uses of Drugs/Devices: In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA approved package insert for each drug/device for full prescribing/utilization information.

It is the policy of the Rush University Office of Interprofessional Continuing Education to ensure that its CE activities are independent, free of commercial bias and beyond the control of persons or organizations with an economic interest in influencing the content of CE. Everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest (including but not limited to pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic) within the preceding 12 months.

The course directors, planners and faculty of this activity have the following relevant financial relationships to disclose.

Thomas E. Witzig, MD
Research Grant: Celgene, Novartis, Acerta - for research trial expenses, no personal money received
Consultant: Celgene (personally uncompensated)

Michaela Ryan, PhD
Nothing to disclose

Beth-Anne M. Christopher, MS, RN, CNL
Nothing to disclose

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of 1.0 continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of 1.0 continuing education unit(s) in Pharmacy. UAN: JA0000275-0000-18-130-H01-P.

Instructions for Receiving Credit

Participants must complete and submit the online CE evaluation form at the conclusion of the activity and achieve a passing score of 75% or better. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Inc., Celgene Corp., Novartis, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., AbbVie, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Rush University, PleXus Communications, and/or the commercial supporters. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Rush University, PleXus Communications and/or the commercial supporters. Rush University’s ANCC accreditation status does not imply endorsement by Rush or ANCC of any commercial products displayed in conjunction with this activity. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Contact Information for Questions About the Activity

Info@plexuscomm.com
866-607-4333

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

1.25 CME / CNE
Vindico
Improving Colorectal Cancer Screening and Prevention: Advances in Polyp Detection and Resection

Improving Colorectal Cancer Screening and Prevention: Advances in Polyp Detection and Resection

Start

Activity Details

Free CME/CNE
1.25 AMA PRA Category 1 Credit(s)
1.25 Contact Hour(s)
Released: October 1, 2018
Expires: October 1, 2019
75 minutes to complete

Provider Statement

This continuing education activity is provided by

Support Statement

This continuing educational activity is supported by an educational grant from Aries Pharmaceuticals, Inc.

Activity Chair

(1) Latest Advances to Improve Polyp Resection
(2) Case Presentations

Douglas K. Rex, MD
Distinguished Professor of Medicine
Indiana University
Indianapolis, IN
Disclosures:
Consulting Fee: Aries Pharmaceuticals, Inc, Boston Scientific, Braintree, Cosmo Pharmaceuticals, Olympus
Contracted Research: Boston Scientific, Braintree, EndoAid Ltd, Medivators, Medtronic, Olympus, PAION, Sebela

Faculty

Increasing Adenoma Detection Rates: Improving Colorectal Cancer Outcomes
David A. Johnson, MD, MACG, FASGE, FACP
Professor of Medicine
Chief of Gastroenterology
Eastern Virginia Medical School
Norfolk, VA
Disclosures:
Consulting Fee: Aries Pharmaceuticals, Inc, CRH Medical, Pfizer, WebMD/Medscape


Tools and Devices to Improve Adenoma Detection Rates
Prateek Sharma, MD
Professor of Medicine
University of Kansas School of Medicine
Kansas City, MO
Disclosure: No relevant financial relationships to disclose.

Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Nurse Planners

Barbara A. Niedz, PhD, RN, CPHQ
Disclosure: No relevant financial relationships to disclose.

Kelli C. Kneisel, FNP
Disclosure: No relevant financial relationships to disclose.

Medical Writer

Valerie Zimmerman, PhD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education and the American Nurses Credentialing Center’s Standards for Commercial Support, all CME/CNE providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME/CNE content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME/CNE activity content over which the individual has control.

Unlabeled and Investigational Usage

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education, LLC, is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education will provide 1.25 contact hours for nurses.

There is no non-commercial support for this activity.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

This enduring material is approved for 1 year from the date of original release, October 1, 2018 to October 1, 2019.

How to Participate in This Activity and Obtain CME/CNE Credit

To participate in this CME/CNE activity, you must answer the pre-activity questions, read the objectives and articles, and complete the post-activity questions and evaluation in their entirety. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the post-activity questions correctly. Upon receipt of the completed materials, if a satisfactory score on the post-activity is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ or Learner-Paced Contact Hours certificate immediately.

Overview

Colorectal cancer (CRC) is the third most common type of cancer worldwide and the second deadliest form of cancer in the United States. Studies on CRC screening show that for every 1% increase in a physician’s adenoma detection rate (ADR), the risk of colon cancer developing in their patients over the next year decreases by 3%. Thus, if physicians are proficient at finding and removing precancerous polyps during colonoscopy, cancer is less likely to develop. However, estimates suggest that up to 25% of adenomas are missed with current colonoscopy technologies, primarily due to poor visualization in folds and other difficult-to-detect areas. Modifiable factors to improve detection rates include colonoscopy team behaviors during procedures, endoscope design, and targeted education. Technological advances and strategies to improve visualization, as well as field of view, have improved detection rates in recent years, and more strategies are in development. In addition, when an adenoma is detected, the use of injectable solutions, such as artificial tears, hetastarch, or viscous agents with medium-chain triglycerides and methylene blue, may provide long-lasting submucosal lift and cushion to reduce the risk of perforation during removal. This educational activity will focus on strategies to improve polyp identification and reduce endoscopic resection risks.

Target Audience

This program is designed for gastroenterologists, nurses, and other health care professionals involved in the screening of patients for colorectal cancer (CRC).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:
Physician Learning Objectives:

  • Examine trends in the incidence rates of CRC as well as the importance of appropriate screening and early detection.
  • Utilize appropriate strategies and devices to improve adenoma detection rates (ADR).
  • Identify polyps that may be better suited for endoscopic versus surgical removal.
  • Apply the latest technical advances to the resection of gastrointestinal polyps for cancer prevention.

Nurse Learning Objectives:

  • Examine trends in the incidence rates of CRC as well as the importance of appropriate screening and early detection.
  • Utilize appropriate strategies and devices to improve ADR.
  • Review the latest technical advances for the resection of gastrointestinal polyps for cancer prevention.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2018 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.25 CME
University of Nebraska Medical Center
The Next Steps in CAR T-Cell Therapy for the Treatment of Patients With Lymphoma

The Next Steps in CAR T-Cell Therapy for the Treatment of Patients With Lymphoma

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credits
Released: August 31, 2018
Expires: August 31, 2019
20 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Provider

This activity is jointly provided by the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Target Audience

The target audience for this activity is for community and academic medical oncologists, hematologists, advanced practitioners, and other clinicians who treat patients with lymphoma.

Learning Objectives

After completing this activity, participants should be better able to:

  • Review clinical trial data that led to approval of CAR T-cell–based therapies for the treatment of patients with lymphoma
  • Evaluate emerging clinical data and novel approaches to CAR T-cell therapy for patients with lymphoma, including various combination strategies being examined
  • Develop strategies to mitigate adverse events often encountered with the use of CAR T-cell therapy, including cytokine release syndrome and neurotoxicity

Activity Description

Expert Insights is an interview involving 2 world renowned experts actively engaged in treatment of patients with lymphoma. This discussion features expert summary and interpretation of data presented during the 2018 Pan Pacific Lymphoma Conference in Hawaii, as well as provide guidance on the optimal use of current and emerging therapies.

Statement of Educational Need

CD19-targeted CAR T cells have emerged as a highly effective therapy in patients with NHL. However, multiple CAR T-cell technologies are under investigation, all with various doses, lymphodepleting chemotherapy, disease subtypes under exploration, and adverse event profiles. Thus, clinicians treating patients with aggressive NHL need expert guidance to evaluate clinical data on CAR T-cell therapy and plan strategies to appropriately integrate these approaches into practice now and as they become available.

Faculty

Julie M. Vose, MD, MBA - Moderator
Neumann M. and Mildred E. Harris Professor
Chief, Division of Oncology and Hematology Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Grants/Research Support: Acerta Pharma, Bristol-Myers Squibb Company, Celgene Corporation, Incyte Corporation, Kite Pharma, Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Novartis, Seattle Genetics, Inc.

Consultant Fees, Honorarium: AbbVie Inc., Epizyme, Inc., Karyopharm Therapeutics, Legend Pharmaceuticals, Novartis, Roche, Sandoz, Vaniam Group LLC


Sattva S. Neelapu, MD
Professor
Deputy Department Chair ad interim
Director of Laboratory and Translational Research
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Grants/Research Support, Advisor: Acerta Pharma, Bristol-Myers Squibb Company, Cellectis, Gilead, Karus, Kite, A Gilead Company, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Poseida

Consultant, Advisor: Celgene Corporation, Kite, A Gilead Company, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Novartis, Unum Therapeutics


Conflict of Interest Policy/Disclosure Statement

As a provider accredited by ACCME, the University of Nebraska Medical Center (UNMC), Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC, Center for Continuing Education.

The following indicates the disclosure declaration information and the nature of those commercial relationships.

All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Statement of Commercial Support

Educational grant support provided by Celgene Corporation and Kite, A Gilead Company.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions About the Activity

University of Nebraska Medical Center, Center for Continuing Education
Brenda Ram, CMP, CHCP
bram@unmc.edu
402-559-9250

Bio Ascend
meetings@bioascend.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Pages